What's the interaction between ruxolitinib and azacitidine?

How does ruxolitinib affect azacitidine treatment outcomes?

Ruxolitinib is a JAK inhibitor used in myelofibrosis and polycythemia vera. Azacitidine is a hypomethylating agent for myelodysplastic syndromes and acute myeloid leukemia. Their combination has been tested in patients with myelofibrosis who also have high-risk cytogenetic features or mutation profiles.

Studies show the pairing improves overall response rates and spleen volume reduction compared to azacitidine alone.